Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher

Showing results (251-260 of 6,822) with videos related to

Pageof 683
Sort By:
Nature Reviews. Drug Discovery|August 5, 2022
Pliant's integrin inhibitor boosted by phase II IPF dataAsher Mullard
Nature Reviews. Drug Discovery|August 5, 2022
BCMA-targeted bispecific gets first green light, in the EUAsher Mullard
Lancet (London, England)|June 8, 2020
COVID-19 vaccine development pipeline gears upAsher Mullard
Nature Reviews. Drug Discovery|June 10, 2020
Targeted degraders clear first safety hurdlesAsher Mullard
Nature Reviews. Drug Discovery|August 14, 2021
What's next for an immuno-oncology powerhouse?Asher Mullard
Paediatric Respiratory Reviews|June 27, 2006
Is hygiene damaging to your health?Innes Asher
Studies in Health Technology and Informatics|October 2, 2004
Is this as good as it gets? It may beMarc Asher
Nature Reviews. Drug Discovery|December 2, 2022
FDA approves anti-CD3 antibody to delay type 1 diabetes onsetAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
FDA approves fifth RNAi drug - Alnylam's next-gen hATTR treatmentAsher Mullard
Nature Reviews. Drug Discovery|January 10, 2023
GPRC5D-targeted bispecific bolsters T-cell-engager pipelineAsher Mullard
Pageof 683

Showing results (251-260 of 6,822) with videos related to

Sort By:
Pageof 683
Nature Reviews. Drug Discovery|August 5, 2022
Pliant's integrin inhibitor boosted by phase II IPF dataAsher Mullard
Nature Reviews. Drug Discovery|August 5, 2022
BCMA-targeted bispecific gets first green light, in the EUAsher Mullard
Lancet (London, England)|June 8, 2020
COVID-19 vaccine development pipeline gears upAsher Mullard
Nature Reviews. Drug Discovery|June 10, 2020
Targeted degraders clear first safety hurdlesAsher Mullard
Nature Reviews. Drug Discovery|August 14, 2021
What's next for an immuno-oncology powerhouse?Asher Mullard
Paediatric Respiratory Reviews|June 27, 2006
Is hygiene damaging to your health?Innes Asher
Studies in Health Technology and Informatics|October 2, 2004
Is this as good as it gets? It may beMarc Asher
Nature Reviews. Drug Discovery|December 2, 2022
FDA approves anti-CD3 antibody to delay type 1 diabetes onsetAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
FDA approves fifth RNAi drug - Alnylam's next-gen hATTR treatmentAsher Mullard
Nature Reviews. Drug Discovery|January 10, 2023
GPRC5D-targeted bispecific bolsters T-cell-engager pipelineAsher Mullard
Pageof 683